In This Article:
As the U.S. market navigates a landscape of tariff exemptions and fluctuating tech stock performance, investors are keenly observing opportunities that may arise from these developments. For those interested in smaller or newer companies, penny stocks — despite their somewhat outdated moniker — remain a relevant investment area. When supported by solid financial health, these stocks can offer a blend of value and growth potential that might not be as prominent in larger firms.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
Safe Bulkers (NYSE:SB) | $3.48 | $364.86M | ★★★★☆☆ |
Tuya (NYSE:TUYA) | $2.02 | $1.2B | ★★★★★★ |
CI&T (NYSE:CINT) | $4.87 | $651.45M | ★★★★★☆ |
Smith Micro Software (NasdaqCM:SMSI) | $0.796 | $14.15M | ★★★★☆☆ |
Global Self Storage (NasdaqCM:SELF) | $4.93 | $55.56M | ★★★★★☆ |
Flexible Solutions International (NYSEAM:FSI) | $3.83 | $48.44M | ★★★★★★ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.33 | $70.67M | ★★★★★★ |
BAB (OTCPK:BABB) | $0.7755 | $5.63M | ★★★★★☆ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $226.43M | ★★★★★★ |
Lifetime Brands (NasdaqGS:LCUT) | $3.99 | $88.43M | ★★★★★☆ |
Click here to see the full list of 795 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
Organogenesis Holdings
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of $540.29 million.
Operations: The company generates revenue primarily from its Regenerative Medicine segment, amounting to $482.04 million.
Market Cap: $540.29M
Organogenesis Holdings Inc., with a market cap of US$540.29 million, recently joined the S&P Biotechnology Select Industry Index, highlighting its presence in the sector. Despite being unprofitable and experiencing high share price volatility, it reported a net income of US$7.67 million for Q4 2024, a turnaround from the previous year's loss. The company is debt-free and has strong short-term assets exceeding liabilities by over US$200 million, providing financial stability. However, significant insider selling raises concerns about internal confidence despite forecasts of substantial earnings growth and trading at good value compared to peers.
-
Take a closer look at Organogenesis Holdings' potential here in our financial health report.
-
Gain insights into Organogenesis Holdings' future direction by reviewing our growth report.
Alight
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Alight, Inc. is a technology-enabled services company operating globally with a market cap of approximately $2.64 billion.